Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick

    Editors Pick - Page 25

    Pfizer generic unit Upjohn to merge with Mylan; new entity aims revenue of 19-20 billion Dollar for 2020

    Pfizer generic unit Upjohn to merge with Mylan; new entity aims revenue of 19-20 billion Dollar for 2020

    Medical Dialogues Bureau31 July 2019 10:18 PM IST
    New Delhi: Mylan N.V. and Pfizer Inc have announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic...
    Novartis Expiry of Patent for Blockbuster Vildagliptin to Clear Way for Competitors

    Novartis Expiry of Patent for Blockbuster Vildagliptin to Clear Way for Competitors

    Farhat Nasim30 July 2019 2:08 PM IST
    New Delhi: The patent protection of blockbuster anti-diabetic drug Vildagliptin manufactured by the Swiss drugmaker, Novartis, will soon expire on...
    Cipla asks Government to increase fund allocation for healthcare sector

    Cipla asks Government to increase fund allocation for healthcare sector

    Medical Dialogues Bureau29 July 2019 6:09 PM IST
    Addressing shareholders in the company's Annual Report for 2018-19, Cipla Chairman Y K Hamied said basic healthcare in the country will always require...
    Violation of guidelines for OTC sale of antibiotics to draw regulatory action- Health Minister

    Violation of guidelines for OTC sale of antibiotics to draw regulatory action- Health Minister

    Farhat Nasim28 July 2019 4:30 PM IST
    New Delhi: Through a recent written reply, Health Minister Dr Harsh Vardhan has apprised the parliament about the power possessed by the State...
    DOP junks Geltec plea against NPPA decision on retail price of Ibuprofen Soft Gelatin Capsules

    DOP junks Geltec plea against NPPA decision on retail price of Ibuprofen Soft Gelatin Capsules

    Farhat Nasim28 July 2019 11:30 AM IST
    New Delhi: Through a recent decision, the Department of Pharmaceuticals (DOP) has rejected the review application filed by Geltec Private Limited...
    22-member Committee Constituted to guide CDSCO on Medical Device Regulation

    22-member Committee Constituted to guide CDSCO on Medical Device Regulation

    Farhat Nasim27 July 2019 1:09 PM IST
    New Delhi: To advice the apex drug regulator, Central Drugs Standard Control Organisation (CDSCO) on matters related to the regulation and...
    Apixaban Patent: Natco gets HC relief for its upcoming medicine Apigat

    Apixaban Patent: Natco gets HC relief for its upcoming medicine Apigat

    Farhat Nasim26 July 2019 3:00 PM IST
    NEW DELHI: Days after ending a patent row over its cancer drug Regonat with Bayer, drugmaker, Natco Pharma is reported to have now been embroiled in a...
    Man dies after Pharmacist administers painkiller injection; case booked

    Man dies after Pharmacist administers painkiller injection; case booked

    Farhat Nasim25 July 2019 4:44 PM IST
    Chennai: A 52 years old pharmacist has been arrested following the death of a man who was administered a painkiller injection by him. According to...
    NPPA notices worth Rs 101 crore sent to Biocon, Lupin, Dr Reddys, others for skipping regulatory nod-Minister 

    NPPA notices worth Rs 101 crore sent to Biocon, Lupin, Dr Reddys, others for skipping regulatory nod-Minister 

    Medical Dialogues Bureau24 July 2019 12:16 PM IST
    NPPA has so far issued demand notices for an amount of Rs 101 crore against defaulting companies. Out of this, an amount of Rs 5.56 crore has been...
    Doctors should prescribe only generic medicines: CDSCO Committee

    Doctors should prescribe only generic medicines: CDSCO Committee

    Medical Dialogues Bureau23 July 2019 5:36 PM IST
    The generic medicines are at least 90 per cent cheaper than branded medicines. There are nearly 600 types of generic medicines and about 23 kinds of...
    Government BANS use of decade old antibiotic COLISTIN in animal feeding, fishing

    Government BANS use of decade old antibiotic COLISTIN in animal feeding, fishing

    Farhat Nasim22 July 2019 3:24 PM IST
    New Delhi: Through a recent Gazette notification, the Union Health Ministry has imposed a ban on popular antibiotic Colistin and its formulations in...
    Delhi HC restricts Lee Pharma from infringing copyright of Mankind Pharma

    Delhi HC restricts Lee Pharma from infringing copyright of Mankind Pharma

    Medical Dialogues Bureau21 July 2019 4:30 PM IST
    Justice Prathiba M Singh said considering the evidence and the content of the website of Lee Pharmaceuticals of Lee House being identical, a permanent...
    PrevNext

    Popular Stories

    Coronavirus pandemic: Govt delegates more powers to NPPA to control, increase API production by manufacturers

    Coronavirus pandemic: Govt delegates more powers to NPPA to control, increase API production by...

    NPPA fixes prices of 29 formulations under DPCO, check out details

    NPPA fixes prices of 29 formulations under DPCO, check out details

    Metropolis Healthcare Q2 profit up 44 pc to Rs 43 crore

    Metropolis Healthcare Q2 profit up 44 pc to Rs 43 crore

    Lupin gets USFDA EIR for Nagpur Facility

    Lupin gets USFDA EIR for Nagpur Facility

    AstraZeneca gets USFDA nod for Koselugo for paediatric patients with neurofibromatosis type 1

    AstraZeneca gets USFDA nod for Koselugo for paediatric patients with neurofibromatosis type 1

    Aurobindo Pharma gets USFDA nod for Fluoxetine Tablets

    Aurobindo Pharma gets USFDA nod for Fluoxetine Tablets

    SMS Pharma updates against USFDA statement on Ranitidine

    SMS Pharma updates against USFDA statement on Ranitidine

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok